Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.
News
Leading Cambridge and international intellectual property (IP) firm Marks & Clerk is to host the Cambridge IP Summit, taking place on Thursday 10 October at the Hilton Hotel, Cambridge.
The event aims to build upon the success of last year’s summit, which brought leading businesses from Cambridge and beyond together to discuss how to protect high-tech innovation.
Westbury, NY – Oct. 2, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Lori Ball as its chief operating officer (COO). In her new position, Ms. Ball will be responsible for providing leadership and strategic direction on operational and business decisions, including growth planning, business and organizational development, risk management, and quality control.
Louvain la Neuve, Belgium, 1st October 2019 / Sciad Newswire / N-SIDE, provider of innovative software and strategic consulting services, announced that AstraZeneca has signed an agreement to implement the N-SIDE Suite for Clinical Trials. Within the scope of this agreement, AstraZeneca will use specifically the N-SIDE Supply and Dashboard Apps in order to design, plan and monitor their clinical trial supply chain.
Cambridge, UK, 30 September 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the full commercial licensing to Glenmark Pharmaceuticals, a global innovative pharmaceutical company, of its gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line. Terms of the agreement were based on stringent evaluation of the cell line by Glenmark to assess its suitability for adoption into the Company’s biomanufacturing processes.
Today, Stevenage Bioscience Catalyst (SBC) has announced the appointment of two new Non-Executive Directors (NEDs) to its Board. Clare Terlouw, Head of Corporate Development at Syncona Investment Management Limited and Jon Green, Chair of One Nucleus, will be joining the SBC Board on 1st October 2019.
Cambridge, UK; September 27, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, will present a poster today that details an expanding body of evidence for the dual mechanism-of-action of the company’s anti-ICOS program, KY1044. The poster will be presented at the Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CICON), being held at the Espace Grande Arche in Paris September 25-28, 2019.
AMSBIO has introduced a new range of proprietary reagents designed for researchers investigating targeted cancer therapy.
BioIVT will help to generate drug discovery target validation data and characterize novel therapeutics
Royston, UK – Sept. 24, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined UK Medicines Discovery Catapult’s Discovery Services Platform, partnering with other best-in-class service providers to help improve preclinical drug discovery success rates.